IGF1R and central nervous system cancer: Employing this strategy, they developed an antisense ODN (oligodeoxynucleotide) against the IGF-1R and in a Phase 0 human clinical trial demonstrated that ex-vivo IGF-1R antisense ODN treatment with patient derived autologous glioma cells safely induced apoptosis and a host response [4].